Related Experiment Video

Updated: Aug 16, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels?

Mehmet Kanbay1, Gürden Gür, Muammer Yücel

  • 1Department of Internal Medicine, Baskent University Faculty of Medicine, Ankara, Turkey. drkanbay@yahoo.com

Digestive Diseases and Sciences
|July 29, 2005
PubMed

Insights

Eradicating Helicobacter pylori infection improved lipid profiles and reduced C-reactive protein (CRP) levels. This suggests H. pylori may be an independent risk factor for coronary artery disease.

Area of Science:

  • Cardiology
  • Gastroenterology
  • Infectious Diseases

Background:

  • The link between Helicobacter pylori infection and coronary artery disease risk factors remains unclear.
  • Investigating the impact of H. pylori eradication on cardiovascular markers is crucial.

Purpose of the Study:

  • To determine if eradicating H. pylori infection influences serum lipid levels and C-reactive protein (CRP).
  • To assess H. pylori's role as a potential independent risk factor for coronary artery disease.

Main Methods:

  • Seventy-eight H. pylori-positive patients received a 14-day eradication therapy.
  • Serum total cholesterol, HDL, LDL, triglycerides, and CRP were measured pre- and post-treatment.
  • Patients were divided into eradicated (Group A) and non-eradicated (Group B) groups.

Main Results:

  • Group A (eradicated) showed significant decreases in CRP and increases in HDL levels (P < 0.05).
  • No significant changes in LDL, total cholesterol, or triglycerides were observed in either group.
  • Group B (non-eradicated) showed no significant changes in CRP or HDL levels.

Conclusions:

  • H. pylori infection may negatively impact lipid metabolism, potentially increasing atherosclerosis risk.
  • H. pylori eradication led to favorable changes in CRP and HDL, suggesting a link to cardiovascular health.
  • H. pylori infection is proposed as an independent risk factor for coronary artery disease.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...